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Abstract: A vast amount of data on nanomedicines is being generated and published, and natural
language processing (NLP) approaches can automate the extraction of unstructured text-based
data. Annotated corpora are a key resource for NLP and information extraction methods which
employ machine learning. Although corpora are available for pharmaceuticals, resources for
nanomedicines and nanotechnology are still limited. To foster nanotechnology text mining
(NanoNLP) efforts, we have constructed a corpus of annotated drug product inserts taken from
the US Food and Drug Administration’s Drugs@FDA online database. In this work, we present
the development of the Engineered Nanomedicine Database corpus to support the evaluation
of nanomedicine entity extraction. The data were manually annotated for 21 entity mentions
consisting of nanomedicine physicochemical characterization, exposure, and biologic response
information of 41 Food and Drug Administration-approved nanomedicines. We evaluate the
reliability of the manual annotations and demonstrate the use of the corpus by evaluating two
state-of-the-art named entity extraction systems, OpenNLP and Stanford NER. The annotated
corpus is available open source and, based on these results, guidelines and suggestions for future
development of additional nanomedicine corpora are provided.
Keywords: nanotechnology, informatics, natural language processing, text mining, corpora
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Nanotechnology is enabling new strategies to detect and treat disease through
multifunctional (eg, targeted, activatable, diagnostic, and therapeutic) drug design.
Formulating a drug as a nanomedicine can also improve its therapeutic index by changing its stability, pharmacokinetics, and toxicity. For several decades, researchers have
primarily designed new nanomedicines based on an empirical approach. However, the
number of possible nanomedicine formulations continues to increase exponentially
as new nanomaterials, surface coatings, bioconjugates, and drug combinations are
developed. As a consequence, experimentally assessing all possible nanomedicine
formulations for efficacy and safety is not feasible or realistic. There is a critical need
to automatically extract information and synthesize knowledge and trends in nanomedicine research to rationally prioritize testing and development.
Natural Language Processing (NLP) approaches can semi-automate the process of
converting text-based unstructured data (eg, full-text articles) to structured data (eg,
tables). Interest in applying NLP techniques to nanotechnology has increased over the
years, with a number of systems developed for nanomedicine information extraction
and nanotechnology patent mining.1 Most NLP algorithms rely on annotated corpora for
both training and evaluation of the system. Despite development of several NanoNLP
systems, only one nanotechnology-related corpus has been described in the literature.2
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Motivated by the need for a nanomedicine corpus, we present
the Engineered Nanomedicine Database (END).
The main objective of this paper is to propose a framework for creating an annotated corpus for nanomedicine
entity extraction. Toward this objective, we validate a manually annotated corpus of US Food and Drug Administration
(FDA)-approved nanomedicines from drug product inserts
collected from the Drugs@FDA Database.3 The extracted
entities consist of nanoparticle physicochemical properties,
exposure parameters, and biologic response information for
41 drugs. We evaluate the precision, recall, and F-measure
between expert and non-expert generated annotations and
evaluate the performance of two state-of-the-art named entity
extraction systems applied to the corpus. To promote future
development of nanomedicine corpora and entity extraction
systems, we provide the expert annotated corpus as open
source (http://rampages.us/nanoinformatics/resources).
The remainder of this paper is as follows. First, we
describe related work associated with entity extraction.
Second, we describe our method in developing the END
dataset. Third, statistical analysis of the annotation process
and the contents of the completed END corpus are presented.
Finally, use of the corpus for creation of a named entity recognition (NER) system tailored to extracting nanomedicine
data is discussed.

Materials and methods
Dataset
The documents selected for annotation were drug product
labels for 41 nanomedicines that are currently approved
for clinical use by the FDA. The labels were obtained from
the Drugs@FDA online database. This document type was
chosen for two reasons: compared to nanomedicines in the
pipeline, FDA-approved nanomedicines are 1) expected

to have the most number of unique publications in the
literature; 2) already being prescribed by physicians, and
therefore, mentions could be contained in clinical notes.
The list of nanomedicines chosen was based on review
articles.4,5 The annotated drug product labels described
nanomedicines consisting of liposomes, micelles, polymer
conjugates, protein conjugates, and nanoparticles, which are
listed in Table 1. The extracted entities relate to nanoparticle
physicochemical properties, exposure, pharmacokinetics,
and biologic response in addition to description information.
A complete list of these entities is shown in Table 2.

Annotation process
To develop an entity extractor, a training set composed
of relevant texts that have been manually annotated by
domain experts is required. Manually annotated corpora
are traditionally prepared by the NLP community through
collective shared tasks. When conducted by individuals, it
has be reported to take more than 10 hours to annotate a
single research paper.2 Recruiting professional nanomedicine
researchers to donate this time is challenging; therefore, we
hypothesized that a potential solution could be to train nonexpert (student) annotators. It has been suggested that, with
training, annotation tasks can be crowdsourced to non-experts
to build annotated corpora of biomedical literature.6,7 In this
work, we assessed the quality of annotations generated by
non-experts to those of a domain expert on texts describing
nanomedicines. The annotators included three undergraduate research assistants and one professor from the Virginia
Commonwealth University Department of Chemical and Life
Science and Engineering. The research assistants were entering their junior year and were given training in annotation as
outlined in the following section. The General Architecture
for Text Engineering (GATE)8 open source, annotation,

Table 1 US FDA-approved nanomedicines from the year 1975 to 2013
Platform

Drug

Conjugate
Antibody–drug
Polymer–aptamer
Polymer–protein
Protein–drug
Lipid
Liposome
Micelle
Nanocrystal
Nanoparticle
Iron
Polymer

Adcetris®, Bexxar®, Kadcyla®, Zevalin®
Macugen®
Adagen®, Cimzia®, Krystexxa®, Mircera®, Neulasta®, Oncaspar®, Pegasys®, PEG-Intron®, Somavert®
Abraxane®, Ontak®
Abelcet®, AmBisome®, Amphotec®, DaunoXome®, DepoCyt®, DepoDur®, Diprivan®, Doxil®, Marquibo®, Visudyne®
Estrasorb™, Taxotere®
Emend®, Megace ES®, Rapamune®, TriCor®, TriGlide®
Feraheme®, Ferrlecit®, Venofer®
Elestrin®
Copaxone®, Eligard®, Renagel®, Welchol®

Abbreviation: FDA, US Food and Drug Administration.
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Table 2 Extracted nanomedicine entities
Class

Entity

Nanomedicine description

Company
FDA approval date
Trade name
US patent
Active ingredient
Core composition
Molecular weight
Nanoparticle
Particle diameter
Surface coating
Dose
Route of administration
AUC
Clearance
Cmax
Elimination half-life
Plasma half-life
Tmax
Volume of distribution
Adverse reaction
Indication

Nanoparticle physicochemical characterization

Exposure
Pharmacokinetics

Biologic response

Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured
in blood; FDA, US Food and Drug Administration;Tmax, time to reach Cmax.

and development environment for computational language
processing was used to manually annotate the drug product
labels. An example of annotation is presented in Figure 1. The
entity annotation guidelines, which include entity definitions
and annotation rules (Table 3), were developed to reduce
potential interpretation differences between annotators.

Annotator training
The following procedure was employed when training the
students:
• “Preannotation guideline discussion phase:” In this phase,
orthography and grammar rules, multiword entity rules,
and definitions of entities were discussed. All students
completed this phase.
• “Pilot annotation phase:” In this phase, the annotators
were trained on six entities (active ingredient, dose,
indication, nanoparticle, route of administration, trade
name). Their annotations were compared with the
expert’s annotations, and all differences were discussed
with them. All students completed this phase.
• “Annotation phase:” In this phase, all 21 entities were
given to the annotators. Orthography and grammar rules,
multiword entity rules, and definitions of entities were
again discussed. The annotators were also informed that
if they had any questions, they were to ask the expert
annotator. All questions and responses were circulated
among all three of the annotators. One student fully completed and two students partially completed this phase.
International Journal of Nanomedicine 2017:12

Results
Characteristics of corpus
Table 4 shows a high-level breakdown of the expert-annotated
drug label inserts within the END corpus. Within the 41 drug
label inserts, there are 28,276 sentences and 465,890 words
and a total of 22,033 annotations. On average, each drug
label contains 690 (SD 496) sentences, 11,363 (SD 5,897)
words, and 537 (SD 310) annotations. The largest class of
nanomedicines, liposomes, was also examined to determine
if restricting to a subset could be representative of the corpus
overall. Table 5 shows the number of annotated mentions,
the number of unique mentions, and the number of labels
containing mentions for each entity. Not all labels contained
a mention for all 21 entity types. The number of mentions
across the drug labels varied from 6,689 (adverse reaction)
to 7 (particle diameter). The unique types of mentions also
varied, with the largest number annotated for adverse reaction
where 1,773 of the 6,689 mentions were unique.

Evaluation of non-expert annotations
We evaluated the annotation agreement using precision,
recall, and F-measure, which were calculated using the GATE
framework. Precision measures the number of correctly
identified entities as a percentage of the number of items
identified. Recall measures the number of correctly identified entities as a percentage of the total number of correct
entities. F-measure is the harmonic mean between precision
and recall. In this work, we compare the student annotators
to the expert annotator (Table 6) and the student annotators
to other student annotators (Table 7). We do not report the
inter-annotator agreement (eg, Cohen’s Kappa) because
the concept of a nonentity is not defined, and therefore, the
number of words contained in the nonentity is not known.

Demonstration of intended use of the
corpus
We conducted an evaluation of the END corpus on two
state-of-the-art NER systems. We evaluated the Apache
OpenNLP Toolkit and Stanford NER. OpenNLP was created for processing general English natural language text
and includes the NameFinder entity recognizer which uses
a Maximum Entropy supervised learning algorithm to identify named entities in unstructured text.9 Stanford NER is a
Java-based Named Entity Recognizer that has previously
been used to automatically identify general English entities
(eg, person and company names) and biomedical entities
(eg, gene and protein names) from natural language text.10
Stanford NER uses Conditional Random Fields, also known
as CRFClassifier.11
submit your manuscript | www.dovepress.com
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Figure 1 Annotated ferumoxytol drug product label using GATE.
Abbreviation: GATE, General Architecture for Text Engineering.

To evaluate the previously developed entity extractors,
we performed 10-fold cross validation on each of the entity
extraction models developed for the project for those entities
that had at least 45 instances in our dataset. Each instance
contains 10 words to the right and left of the entity. Table 8
shows the F1 score of the OpenNLP and Stanford NER entity
extractors, and the number of instances in the current training
data. The results show that for most entities, the Stanford
NER system obtains a higher F1 score than the OpenNLP
entity extractor for all of the entities evaluated. The Stanford
NER system results show that it is able to identify some
nano-entities very accurately (eg, molecular weight), but
others poorly (eg, core composition). As expected, in general,
entities that had a lower number of instances tended to have
poorer results than those with more instances, although this
is not the case for active ingredient.
The results indicate that further investigation is
required into developing entity extraction methods for
nanomedicines.
Current state-of-the-art named entity extraction systems,
such as Stanford NER and OpenNLP, primarily utilize punctuation, lexical information (eg, previous word), morphologic information (eg, prefix), and orthographic information
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(eg, capitalization) as features into a machine learning
algorithm.12 Although these types of features have been shown
to perform well for general English entities (eg, People,
Locations, and Organizations), they have been shown to be
less useful within the biomedical domain.13 Analysis of the
features utilized by Stanford NER and OpenNLP shows that
Stanford NER incorporates more contextual information as
features than OpenNLP. Our hypothesis is that the incorporation of this additional contextual information may be responsible for Stanford NER systems higher performance.

Discussion
In this work, we created and evaluated an annotated corpus
with nanomedicine and pharmacokinetic parameters.
FDA-approved nanomedicines were chosen due to the
larger number of publications describing these nanomedicines, compared to those still in the development pipeline.
We discovered in our chosen document type (ie, drug product
labels) that a limited number of mentions specific to the
physicochemical properties of nanomedicines are included.
Of the 16 minimum characterization parameters extracted
by other groups, only 5 (core composition, particle diameter,
molecular weight, surface charge, surface chemistry) were

International Journal of Nanomedicine 2017:12
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Table 3 Entity definitions contained in the annotation guidelines
Class

Entity

Description

Nanomedicine description

Company

Company names, including the drug manufacturer and distributor. When annotating,
include any of the following abbreviation (eg, co., corp., inc., LLC)
The year the nanomedicine was approved for clinical use by the US FDA
The trademark name of the nanomedicine. When annotating, do not include the
registered trademark symbol
The US patent number(s) associated with the nanomedicine
The chemical composition of the agent that is providing the pharmacologic effect
The chemical composition of the nanoparticle

FDA approval date
Trade name

Nanoparticle physicochemical
characterization

Pharmacokinetics

Exposure

US patents
Active ingredient
Core composition
(NPO_1808)
Molecular weight
(NPO_1171)
Nanoparticle
(NPO_707)

Particle diameter
(NPO_1539)
Surface coating
(NPO_1962)
AUC (NPO_1523)
Clearance (NPO_1525)
Cmax (NPO_1527)
Elimination half-life
(NPO_1522)
Plasma half-life
(NPO_1589)
Tmax (NPO_1528)
Volume of distribution
(NPO_1524)
Dose
Route of administration

Biologic response

Adverse reaction
Indication

The size of the nanomedicine or components in kilodaltons or other units based on
daltons
The generic name of the nanomedicine (eg, ferumoxytol), the type of nanomedicine
(eg, antibody–drug conjugate, liposome, lipid complex), or the written description of
the nanomedicine (eg, paclitaxel formulated as albumin-bound nanoparticles). Part of
speech variants (eg, liposomal vs liposome) should also be annotated
The size of the nanomedicine or components in nanometers or other units based on
meters
The chemical composition (eg, polyethylene glycol [PEG]) of the surface coating of
the nanomedicine. When annotating, include the abbreviations
Area under the curve. The total drug concentration over time
The volume of blood from which a drug is irreversibly cleared
The maximum concentration measured in the blood
The time at which half of the administered dose remains in the body
The time at which half of the maximum concentration of the drug (systemically
available) remains in the plasma. Also referred to as terminal half-life
The time to reach Cmax
The theoretical volume of the compartment the drug appears to fill as related to the
concentration measured in the blood. Vd = dose/Cmax
The administered mass, volume, and/or concentration of the nanomedicine or other
described drugs. Annotations should include units (eg, 5 mg)
The method in which the nanomedicine is administered to patients. Possible routes
of administration include: dermal (skin), SC, oral (by mouth), IM, IT, IV, intravitreal
Nontherapeutic/off-target/side effects or toxic injury due to taking the nanomedicine
The disease(s) that the nanomedicine is used to detect, treat, or prevent

Abbreviations: Cmax, maximum concentration measured in blood; FDA, US Food and Drug Administration; IM, intramuscular; IT, intrathecal; IV, intravenous; PEG,
polyethylene glycol; SC, subcutaneous; Vd, volume of distribution; NPO, NanoParticle Ontology.

contained in the drug product labels.1 Particle diameter
had the lowest number of entities due to being mentioned
one to two times in only 6 of the 41 labels. Similarly, only
15 out of the 41 labels described the surface coating. Future
work will include full papers from the primary literature to
develop larger training sets that include data on additional
characterization parameters as well as relation annotations.
The inclusion of relation annotations will facilitate linking
Table 4 Summary of corpus text structure
Metric

Corpus

Liposomes

Number of inserts
Number of annotations
Average number of annotations per insert
Average number of sentences
Average number of words
Time span, year

41
22,033
537
690
11,363
1975–2013

10
4,520
468
542
8,728
1989–2012

International Journal of Nanomedicine 2017:12

the descriptors, that is, physicochemical characterization,
exposure, and biologic response information, with the associated drug.
The 41 nanomedicines included in this corpus were chosen
based on published literature reviews.4,5 More recent reviews
identify additional nanomedicines and their drug product
labels will serve as a test set when evaluating our developed
entity extractor.14,15 The nanomedicines in the END corpus
are all nanostructured compounds used for the treatment or
prevention of disease. We recognize that the definition of
nanomedicine is still not fully established in the research
community. Erring on the side of inclusion, the END corpus
contains conjugate formulations, although PEGylated proteins are not always recognized as nanomedicines.16 Despite
some limitations, the END corpus can serve as a controlled
dataset for developing entity extractors for nanomedicine.

submit your manuscript | www.dovepress.com
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Table 5 Statistics on the 21 annotated entities
Class

Entity

No mentions

No unique mentions

No labels included

Nanomedicine description

Company
FDA approval date
Trade name
US patent
Active ingredient
Core composition
Molecular weight
Nanoparticle
Particle diameter
Surface coating
AUC
Clearance
Cmax
Elimination half-life
Plasma half-life
Tmax
Volume of distribution
Dose
Route of administration
Adverse reaction
Indication

197
34
6,716
31
2,161
89
50
854
7
62
47
49
45
16
56
30
29
2,283
1,192
6,689
1,396

69
19
41
31
61
26
40
42
6
11
46
46
42
15
53
18
27
542
20
1,773
162

41
41
41
8
41
16
34
41
6
15
19
24
20
11
13
14
19
41
41
41
41

Physicochemical characterization

Pharmacokinetic parameters

Exposure
Biologic response

Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured in blood; FDA, US food and drug administration; Tmax, time to reach Cmax.

Overall agreement between the student annotators and
the expert annotator was relatively good in light of the wide
experience gap. Low inter-annotator agreement primarily
correlated with the complexity of the entity definition and the
length of description in the drug product insert. For example, a
common misannotation for dose often included values for the

dosage form, which does not always equal the administered
dose. Misannotations for nanoparticle were due to confusion
with the active ingredient. Contributing factors to the confusion include the label listing the generic name of the nanoparticle as the active ingredient and the student annotators’
limited experience identifying components of nanostructures.

Table 6 Annotation agreement between student and expert annotator
Class

Entity

Precision

Recall

F-measure

Nanomedicine description

Company
FDA approval date
Trade name
US patent
Active ingredient
Molecular weight
Nanoparticle
Particle diameter
Surface coating
AUC
Clearance
Cmax
Elimination half-life
Plasma half-life
Tmax
Volume of distribution
Dose
Route of administration
Adverse reaction
Indication

0.96
0.97
0.99
1
0.89
0.89
0.64
1
0.48
0.82
0.74
0.91
0.80
1
0.91
0.91
0.86
0.95
0.96
0.98
0.95

0.46
1
1
1
0.79
0.69
0.42
0.71
0.27
0.47
0.65
0.63
0.73
0.75
0.56
0.87
0.32
0.49
0.06
0.53
0.55

0.62
0.98
1
1
0.84
0.78
0.51
0.83
0.34
0.60
0.69
0.74
0.76
0.86
0.69
0.89
0.46
0.65
0.11
0.69
0.69

Physicochemical characterization

Pharmacokinetic parameters

Exposure
Biologic response
Total

Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured in blood; FDA, US Food and Drug Administration; Tmax, time to reach Cmax.
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Table 7 Annotation agreement between student annotators
Class

Entity

Precision

Recall

F-measure

Nanomedicine description

FDA approval date
Trade name
US patent
Active ingredient
Molecular weight
Nanoparticle
Particle diameter
Dose
Route of administration
Indication

1
1
1
0.80
0.93
0.63
1
0.99
1
0.77
0.92

0.97
1
1
0.89
0.65
0.68
0.43
0.56
0.67
0.94
0.90

0.99
1
1
0.84
0.77
0.65
0.60
0.72
0.80
0.85
0.91

Physicochemical characterization

Exposure
Biologic response
Total

Abbreviation: FDA, US Food and Drug Administration.

This limited experience also resulted in low inter-annotator
agreement for surface coating. The low precision of surface
coating is skewed due to misannotations contained in one
label (Zevalin). The low recall is more representative, since
the missing annotations for surface coating were consistent
across the labels. Out of all entities, adverse reaction had the
lowest recall. This was attributed to adverse reaction having
the largest number of unique entities and being described in
several sections of the label. Compared to a study reporting
inter-annotator agreement between crowdsourced annotations
and expert annotations, our overall F-measure across all entities was lower (0.69 vs 0.76).6,7 We believe this is in part due
to the inclusion of more complex concepts in our entity set
compared to the biomedical entities, disease and symptom,
which more people are familiar with from life experience.
The agreement across students was higher for the 10 entities
that all students completed across all 41 labels. The trends
observed in the student–student and expert–student agreement

were similar. For example, the entities that presented the most
difficulty and consequently resulted in the highest number of
misannotations between students were active ingredient, dose,
and nanoparticle. The reasons for the high number of false
positives are the same to those described above. The student–
student agreement for indication revealed an opposite result,
low precision and high recall, compared to the expert–student
agreement, high precision and low recall. This was due to the
higher number of misannotations when comparing between
students, compared to missing annotations when comparing
between the expert and students. Overall, the performance
of the students for entities that could describe any drug (eg,
trade name, US patent) was better than for entities specific to
nanomedicines (ie, nanoparticle, particle diameter).

Limitations
Several limitations must be discussed to facilitate the
interpretation of the results of this study. First, the current

Table 8 F-measure of state-of-the-art NER systems
Class

Entity

No mentions

Open NLP

Stanford NER

Nanomedicine description

Company
Trade name
Active ingredient
Core composition
Molecular weight
Nanoparticle
Surface coating
AUC
Clearance
Cmax
Plasma half-life
Dose
Route of administration
Adverse reaction
Indication

197
6,716
2,161
89
50
854
62
47
49
45
56
2,283
1,192
6,989
1,396

0.65
0.72
0.59
0.23
0.58
0.65
0.43
0.26
0.35
0.45
0.47
0.54
0.67
0.10
0.51

0.74
0.81
0.77
0.27
0.84
0.82
0.59
0.41
0.31
0.50
0.67
0.68
0.78
0.12
0.64

Physicochemical characterization

Pharmacokinetic parameters

Exposure
Biologic response

Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured in blood; NER, named entity recognition; NLP, natural language processing.
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dataset consists of entities and their context extracted from
FDA drug labels. It is still unclear if the context describing
the entities within the labels is similar to that within the
primary literature. The next step is to utilize this framework
for a large-scale data creation study that focuses on primary
literature. During this time, we will compare using the drug
label dataset as test data for automatically extracting entities
from labels not in the training set as well as different article
types (eg, preclinical vs clinical).
Second, the size of the dataset is relatively small. However, we believe that this dataset and the framework developed
for its creation can be used to facilitate 1) the development
of additional larger-scale datasets for nanoparticle entity
extraction and 2) the evaluation of current state-of-the-art
NLP methods on secondary bio-focused tasks. For example,
the pharmacokinetic parameters and biologic response entities are not solely relevant to nanomedicines (eg, plasma
half-life, adverse effect). This dataset may be leveraged to
aid in developing systems to extract this information across
a wide variety of different types of medications.
Third, many nanomedicines in the pipeline are not represented by the formulations included in the set based on the current FDA-approved nanomedicines. The language describing
these more sophisticated nanomedicine complexes may differ
from the FDA-approved nanomedicines based on older technology. In addition, these new nanomedicines may receive
FDA approval in the future, and future work will include
active learning to better cover the complete dataset.17

Lessons learned
For this project, we used GATE to manually annotate the
drug product labels.8 The annotation was conducted using
the Windows and Mac operating systems. This caused some
compatibility issues. Future annotations will be conducted
using a single operating system to avoid these difficulties.
In addition, manual annotation is a time-consuming and
sometimes tiresome process. Future work will include
active learning to focus manual annotation efforts on entities
that need more instances to improve the entity recognition
algorithm.
Analysis of current state-of-the-art named entity extraction systems showed that they are not applicable for each
of the different nanomedicine parameters extracted by the
system. Analysis of the parameters also showed that not
all parameters may need a machine learning component to
identify them within the text. For example, out of the 1,192
mentions of Route of Administration, only 20 were unique.
Given the low performance of identifying this entity by the
NER systems, incorporating simple rules and a dictionary for
7526
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a hybrid machine learning/rule-based approach may improve
the overall results of the system.

Conclusion
In this paper, we proposed a framework for creating an
annotated corpus for nanomedicine entity extraction. We
validated our framework by annotating a corpus of FDAapproved nanomedicines from drug product inserts collected
from the Drugs@FDA Database. We annotated the nanoparticle physicochemical properties, exposure parameters, and
biologic response information and evaluated the reliability
of the human ratings. Based on these results, we provided
guidelines and suggestions for future development of additional nanomedicine corpora. We provided both the annotated corpus and the statistical software for their analysis
as open source. Furthermore, we demonstrated the use of
the proposed framework by evaluating two state-of-the-art
named entity extraction systems on the corpus. In the future,
we plan to extend this corpus to include the preclinical and
clinical trial literature.
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